Physician profile
Jignesh D Dalal
NPI 1518909191
$4,183.85
in general payments reported to CMS, 2019-2025
20 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,369 · 2020: $177 · 2021: $1,812 · 2022: $174 · 2023: $242 · 2024: $163 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,467.21 | 2019-2025 | |
| Adaptive Biotechnologies Corporation | $552.00 | 2021 | |
| Amgen INC. | $168.63 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.00 | 2023-2024 | Livtencity, Vonvendi |
| Bayer Healthcare Pharmaceuticals INC. | $121.73 | 2019-2024 | |
| Genzyme Corporation | $114.26 | 2022-2025 | |
| Syndax Pharmaceuticals, INC. | $96.22 | 2025 | Revuforj |
| Csl Behring | $86.05 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $81.79 | 2019-2024 | Ultomiris |
| Novo Nordisk INC | $67.12 | 2021-2025 | Alhemo |
| Merck Sharp & Dohme LLC | $57.81 | 2025 | Prevymis, Zerbaxa |
| Jazz Pharmaceuticals INC. | $57.70 | 2019-2025 | |
| Shire North American Group INC | $30.50 | 2019 | |
| Chiesi USA, INC. | $29.92 | 2023-2025 | Ferriprox |
| Genentech USA, INC. | $23.76 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acrotech Biopharma INC. | $23.69 | 2021 | |
| Emd Serono, INC. | $16.40 | 2022 | |
| Global Blood Therapeutics, INC. | $14.41 | 2021 | |
| Grifols USA, LLC | $13.65 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jignesh Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.